SCHEMBL22360340

SCHEMBL22360340

C/C=N\NCc1cccc(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 2/20 0.53
▸ ALDH1A1 P00352 3/20 0.50
▸ MAPT P10636 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HTT P42858 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ MMP13 P45452 1/20 0.49
▸ CHRM1 P11229 1/20 0.49
▸ CHRM3 P20309 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ TAAR1 Q96RJ0 3/20 0.47
▸ IDO1 P14902 2/20 0.47
▸ AGXT P21549 2/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ ABCB1 P08183 1/20 0.47
▸ ABCG2 Q9UNQ0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20753820 0.84 ALDH1A1 (0.51) CHRM2ALDH1A1MAPTMEN1KMT2A
SCHEMBL29370584 0.79 CHRM2 (0.68) CHRM2ALDH1A1MAPTMEN1KMT2A
SCHEMBL297410 0.79 CHRM2 (0.68) CHRM2ALDH1A1MAPTMEN1KMT2A
SCHEMBL22360336 0.78 ALDH1A1 (0.43) ALDH1A1MMP13KDM4ETAAR1IDO1
SCHEMBL1134127 0.77 CHRM2 (0.74) CHRM2ALDH1A1MEN1KMT2AHTT
SCHEMBL11831753 0.76 CHRM2 (0.51) CHRM2ALDH1A1MAPTMEN1KMT2A
SCHEMBL11831743 0.76 CHRM2 (0.51) CHRM2ALDH1A1MAPTMEN1KMT2A
SCHEMBL18685365 0.75 CHRM2 (0.62) CHRM2ALDH1A1MAPTMEN1KMT2A
SCHEMBL7738530 0.75 CHRM2 (0.62) CHRM2ALDH1A1MEN1KMT2AHTT
Hydrochloric Acid SCHEMBL6122475 0.75 CHRM2 (0.72) CHRM2ALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020167976-A1 THIENO[3,2-B] PYRROLE[3,2-D]PYRIDAZINONE DERIVATIVES AND THEIR USE AS PKM2 DERIVATIVES FOR THE TREATMENT OF CANCER, OBESITY AND DIABETES RELATED DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2020-08-20 — — WO disclosed
Send feedback